| Detailed information |
|---|
| CancerLivER ID | 2166 |
| Biomarker | APO-A1, Apo-A4 |
| Biomarker Name/Symbol (given in Publication) | APO-A1 and Apo-A4 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarkers for diagnosis of HCC with a high sensibility and specificity; but not validated on independent dataset |
| Experimental Condition | HCC v/s other liver disease (cirrhosis/ALD) |
| Cancer type | Hepatocellular carcinoma |
| Regulation | APO-A4 Upregulated and APO-A1 downregulated in HCC patients |
| Level of significance | p < 0.01 |
| Source | Plasma |
| PMID | 21160983 |
| Type of Biomarker | Diagnostic |
| Pathway | signaling pathways, regulatory pathways |
| Cohort | 40 Patients with liver cirrhosis of the three most frequent aetiologies (10 HBV, 16 HCV and 14 ALD) . |
| Sensitivity | 89% |
| Specificity | 81% |
| Accuracy | NA |
| AUC | 0.94 |
| Disease | Human, hepatitis C virus, hepatitis B virus and alcoholic liver disease |
| Year of Publication | 2010 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |